<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00866905</url>
  </required_header>
  <id_info>
    <org_study_id>SCRI BRE 133</org_study_id>
    <nct_id>NCT00866905</nct_id>
  </id_info>
  <brief_title>Ixabepilone and Cyclophosphamide as Neoadjuvant Therapy in HER-2 Negative Breast Cancer</brief_title>
  <official_title>Phase II Study of Ixabepilone and Cyclophosphamide as Neoadjuvant Therapy in HER2-Negative Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>SCRI Development Innovations, LLC</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>SCRI Development Innovations, LLC</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      We propose to evaluate ixabepilone in combination with cyclophosphamide for the neoadjuvant
      treatment of locally advanced breast cancer. In this regimen, ixabepilone is substituted for
      docetaxel, since preclinical and clinical

      studies suggest that ixabepilone is more active than either docetaxel or paclitaxel. The
      combination of ixabepilone and cyclophosphamide could further improve the efficacy of
      non-anthracycline neoadjuvant therapy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In this study, patients with early stage, HER2-negative breast cancer will receive
      neoadjuvant treatment with ixabepilone and cyclophosphamide given every three weeks for a
      total of six cycles. Following surgery patients with hormone receptor-positive tumors will
      receive anti-estrogen treatment. Patients may receive local regional radiation therapy after
      surgery per institutional guidelines at the investigator's discretion. Baseline tumor tissue
      and tumor tissue removed at the time of surgery will be tested by Oncotype Detailed
      Description (DX) assay to determine whether it is predictive of response to this neoadjuvant
      treatment regimen. This study will be one of the first investigations of the combination of
      ixabepilone and cyclophosphamide as neoadjuvant treatment for HER2-negative breast cancer. It
      will examine this treatment regimen for potential advantages gained from substitution of
      ixabepilone for a taxane and use of non-anthracycline agents.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2009</start_date>
  <completion_date type="Actual">October 2014</completion_date>
  <primary_completion_date type="Actual">July 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pathologic Complete Response Rate (pCR)</measure>
    <time_frame>6 months</time_frame>
    <description>Pathologic complete response (pCR) rate will be evaluated per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 following neoadjuvant treatment with six (21-day) cycles of ixabepilone and cyclophosphamide</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Absence of Grade-4 Non-hematologic Toxicity Excluding, Alopecia, Nausea, Vomiting and Bone Pain</measure>
    <time_frame>3 months</time_frame>
    <description>Non hematologic treatment-related grade 4 toxicities measured according to RECIST v1.1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>36 months</time_frame>
    <description>Overall survival (OS) determined as the time between day 1 cycle 1 to the date of death from any cause.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease Free Survival</measure>
    <time_frame>36 Months</time_frame>
    <description>Defined as the time between Day 1 Cycle 1, and date of first documented recurrence, initiation of additional chemotherapy, or death.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">168</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Ixabepilone/Cyclophosphamide</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Systemic Therapy followed by surgery and possible radiation therapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ixabepilone</intervention_name>
    <description>40 mg/m2 IV infusion over 3 hours on day 1 of a 21 day cycle for 6 cycles</description>
    <arm_group_label>Ixabepilone/Cyclophosphamide</arm_group_label>
    <other_name>Systemic therapy</other_name>
    <other_name>Ixempra</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclophosphamide</intervention_name>
    <description>600 mg/m2 IV infusion per institutional guidelines on day 1 of a 21 day cycle for 6 cycles</description>
    <arm_group_label>Ixabepilone/Cyclophosphamide</arm_group_label>
    <other_name>Systemic therapy</other_name>
    <other_name>Cytoxan</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Female patients, age ≥18 years.

          2. Histologically confirmed invasive adenocarcinoma of the breast.

          3. Primary palpable disease confined to a breast and axilla on

             physical examination. For patients without clinically suspicious

             axillary adenopathy, the primary tumor must be larger than 2 cm

             in diameter by physical exam or imaging studies (clinical T2-T3,

             N0-N1, M0). For patients with clinically suspicious axillary

             adenopathy, the primary breast tumor can be any size (clinical

             T1-3, N1-2, M0). (T1N0M0 lesions are excluded.)

          4. Patients without clearly defined palpable breast mass or axillary

             lymph nodes but radiographically measurable tumor masses are

             acceptable. Accepted procedures for measuring breast disease

             are mammography, MRI, and breast ultrasound. This will need to

             be re-evaluated after 3 cycles and prior to surgery.

          5. Eastern Cooperative Oncology Group performance status (ECOG

             PS) 0-2.

          6. No metastatic disease, as documented by complete staging workup

               -  6 weeks prior to initiation of study treatment.

          7. No previous treatment for breast cancer.

          8. HER2-negative tumor status. HER2-negative is defined as:

               -  Immunohistochemical (IHC) 0, IHC 1+ OR

               -  IHC 2+ or IHC 3+ must be confirmed as FISH (fluorescence in situ

             hybridization) negative (defined by ratio &lt;2.2).

          9. Adequate hematologic function with:

               -  Absolute neutrophil count (ANC) &gt;1500/μL.

               -  Platelets ≥100,000/μL.

               -  Hemoglobin ≥10 g/dL.

         10. Adequate hepatic function with:

               -  Serum bilirubin ≤ the institutional upper limit of normal (ULN).

               -  Aspartate aminotransferase (AST) ≤2.5 x institutional ULN.

               -  Alanine aminotransferase (ALT) ≤2.5 x institutional ULN.

         11. Adequate renal function with serum creatinine ≤1.5 x ULN.

         12. Estrogen and progesterone receptor status in the primary tumor

             known or pending at the time of study registration.

         13. Knowledge of the investigational nature of the study and ability to

             provide consent for study participation.

         14. For patients who had, or will have sentinel lymph node and/or

             axillary dissection prior to initiation of study treatment, completion

             at least 4 weeks prior to starting study treatment and well-healed

             wound

         15. Bilateral, synchronous breast cancer is allowed if one primary

             tumor meets the inclusion criteria.

         16. Sufficient archived breast tumor specimen available at baseline

        for the Oncotype DX assay.

        Exclusion Criteria:

          1. Inflammatory breast cancer.

          2. Peripheral neuropathy (motor or sensory) ≥ grade 1 by the

             Common Terminology Criteria for Adverse Events version 3.0

             (CTCAE v 3.0).

          3. Prior radiation that included ≥30% of major bone marrow containing

             areas (pelvis, lumbar, spine).

          4. Chronic use of cytochrome P450 (CYP) 3A4 inhibitors and use of

             the following strong CYP3A4 inhibitors: ketoconazole,

             itraconazole, clarithromycin, atazanavir, nefazodone, saquinavir,

             telithromycin, ritonavir, amprenavir, indinavir, nelfinavir,

             delavirdine, and voriconazole. Use of these agents should be

             discontinued at least 72 hours prior to initiation of study treatment.

          5. Chemotherapy within 5 years of starting study treatment except

             for low doses of agents used for anti-inflammatory indications

             such as rheumatoid arthritis, psoriasis, and connective tissue

             disorders. Although such doses and schedules cannot result in

             myelosuppression, patients must discontinue this therapy while

             they are receiving study treatment.

          6. Known or suspected hypersensitivity to Cremophor®EL

             (polyoxyethylated castor oil) or a drug formulated in

             Cremophor®EL such as paclitaxel, or any other agent given in the

             course of this study.

          7. Pregnancy or breast-feeding. A negative serum pregnancy test

             within 7 days prior to first study treatment (Day 1, Cycle 1) for all

             women of childbearing potential is required. Patients of

             childbearing potential must agree to use a birth control method

             that is approved by their study physician while receiving study

             treatment and for 3 weeks after their last dose of study treatment.

             Patients must agree to not breast-feed while receiving study

             treatment.

          8. Concurrent treatment with an ovarian hormonal replacement

             therapy or with hormonal agents such as raloxifene, tamoxifen or

             other selective estrogen receptor modulator (SERM). Patients

             must have discontinued use of such agents prior to beginning

             study treatment.

          9. History of malignancy treated with curative intent within the

             previous 5 years with the exception of skin cancer, cervical

             carcinoma in situ, or follicular thyroid cancer. Patients with

             previous invasive cancers (including breast cancer) are eligible if

             the treatment was completed more than 5 years prior to initiating

             current study treatment, and there is no evidence of recurrent

             disease.

         10. Uncontrolled intercurrent illness including (but not limited to)

             ongoing or active infection.

         11. Chronic treatment with corticosteroid unless treatment was begun

             &gt;6 months prior to study treatment and is at a low dose (≤20 mg

             methylprednisolone or equivalent).

         12. Use of any investigational agent within 30 days of administration

             of the first dose of study drug.

         13. Requirement for radiation therapy concurrent with neoadjuvant

             study chemotherapy.

         14. Concurrent treatment with any anti-cancer therapy other than

             those agents used in this study.

         15. Inability or unwillingness to comply with study procedures

             including follow-up visits.

         16. Mental condition or psychiatric disorder that would prevent patient

             comprehension of the nature, scope, and possible consequences

             of the study or that would limit compliance with study

             requirements.

         17. Any other disease(s), metabolic dysfunction, or findings from a

        physical examination or clinical laboratory test result that would

        cause reasonable suspicion of a disease or condition that

        contraindicates the use of study drugs, that may affect the

        interpretation of the results, or that renders the patient at high risk

        from treatment complications
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Denise A Yardley, M.D.</last_name>
    <role>Study Chair</role>
    <affiliation>SCRI Development Innovations, LLC</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Aventura Medical Center</name>
      <address>
        <city>Aventura</city>
        <state>Florida</state>
        <zip>33180</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Florida Cancer Specialists</name>
      <address>
        <city>Fort Myers</city>
        <state>Florida</state>
        <zip>33901</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Watson Clinic Center for Cancer Care and Research</name>
      <address>
        <city>Lakeland</city>
        <state>Florida</state>
        <zip>33805</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical Oncology Associates of Augusta</name>
      <address>
        <city>Augusta</city>
        <state>Georgia</state>
        <zip>30901</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northeast Georgia Medical Center</name>
      <address>
        <city>Gainesville</city>
        <state>Georgia</state>
        <zip>30501</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Providence Medical Group</name>
      <address>
        <city>Terre Haute</city>
        <state>Indiana</state>
        <zip>47802</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mercy Hospital</name>
      <address>
        <city>Portland</city>
        <state>Maine</state>
        <zip>04101</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Center for Cancer and Blood Disorders</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20817</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Capital Clinical Research Consortium</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20817</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Louis Cancer Care</name>
      <address>
        <city>Chesterfield</city>
        <state>Missouri</state>
        <zip>63017</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Methodist Cancer Center</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hematology Oncology Associates of Northern NJ</name>
      <address>
        <city>Morristown</city>
        <state>New Jersey</state>
        <zip>07960</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oncology Hematology Care</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45242</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cancer Centers of Southwest Oklahoma</name>
      <address>
        <city>Lawton</city>
        <state>Oklahoma</state>
        <zip>73505</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>South Carolina Oncology Associates, PA</name>
      <address>
        <city>Columbia</city>
        <state>South Carolina</state>
        <zip>29210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chattanooga Oncology Hematology Associates</name>
      <address>
        <city>Chattanooga</city>
        <state>Tennessee</state>
        <zip>37404</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Family Cancer Center</name>
      <address>
        <city>Collierville</city>
        <state>Tennessee</state>
        <zip>38017</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tennessee Oncology</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>South Texas Oncology and Hematology</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78258</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Virginia Cancer Institute</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23235</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 19, 2009</study_first_submitted>
  <study_first_submitted_qc>March 20, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 23, 2009</study_first_posted>
  <results_first_submitted>November 21, 2014</results_first_submitted>
  <results_first_submitted_qc>November 21, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">November 27, 2014</results_first_posted>
  <last_update_submitted>December 5, 2014</last_update_submitted>
  <last_update_submitted_qc>December 5, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 31, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Breast Cancer</keyword>
  <keyword>Ixabepilone</keyword>
  <keyword>Ixempra</keyword>
  <keyword>Cyclophosphamide</keyword>
  <keyword>Cytoxan</keyword>
  <keyword>Neoadjuvant Therapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Epothilones</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Ixabepilone/Cyclophosphamide</title>
          <description>Ixabepilone: 40 mg/m2 via intraveous (IV) infusion over 3 hours
Cyclophosphamide: 600 mg/m2 via IV infusion per institutional guidelines</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="168"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="135"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="33"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Arm/Group 1</title>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="168"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="53" lower_limit="30" upper_limit="79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="168"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="168"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Pathologic Complete Response Rate (pCR)</title>
        <description>Pathologic complete response (pCR) rate will be evaluated per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 following neoadjuvant treatment with six (21-day) cycles of ixabepilone and cyclophosphamide</description>
        <time_frame>6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Ixabepilone/Cyclophosphamide</title>
            <description>Systemic Therapy followed by surgery and possible radiation therapy</description>
          </group>
        </group_list>
        <measure>
          <title>Pathologic Complete Response Rate (pCR)</title>
          <description>Pathologic complete response (pCR) rate will be evaluated per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 following neoadjuvant treatment with six (21-day) cycles of ixabepilone and cyclophosphamide</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="161"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Absence of Grade-4 Non-hematologic Toxicity Excluding, Alopecia, Nausea, Vomiting and Bone Pain</title>
        <description>Non hematologic treatment-related grade 4 toxicities measured according to RECIST v1.1</description>
        <time_frame>3 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Ixabepilone/Cyclophosphamide</title>
            <description>Systemic Therapy followed by surgery and possible radiation therapy</description>
          </group>
        </group_list>
        <measure>
          <title>Absence of Grade-4 Non-hematologic Toxicity Excluding, Alopecia, Nausea, Vomiting and Bone Pain</title>
          <description>Non hematologic treatment-related grade 4 toxicities measured according to RECIST v1.1</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="168"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Fatigue</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Peripheral neuropathy</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Arthralgia/myalgia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Survival</title>
        <description>Overall survival (OS) determined as the time between day 1 cycle 1 to the date of death from any cause.</description>
        <time_frame>36 months</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Disease Free Survival</title>
        <description>Defined as the time between Day 1 Cycle 1, and date of first documented recurrence, initiation of additional chemotherapy, or death.</description>
        <time_frame>36 Months</time_frame>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Ixabepilone/Cyclophosphamide</title>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>CTCAE v 4.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="167"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>FEBRILE NEUTROPENIA</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="167"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>ENTERITIS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="167"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>PERIPHERAL NEUROPATHY</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="167"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>DEPRESSION</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="167"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>CTCAE v 4.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="167" subjects_at_risk="167"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>ANEMIA</sub_title>
                <counts group_id="E1" events="430" subjects_affected="118" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>FEBRILE NEUTROPENIA</sub_title>
                <counts group_id="E1" events="15" subjects_affected="12" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>LEUKOPENIA</sub_title>
                <counts group_id="E1" events="457" subjects_affected="128" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>NEUTROPENIA</sub_title>
                <counts group_id="E1" events="457" subjects_affected="127" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>THROMBOCYTOPENIA</sub_title>
                <counts group_id="E1" events="136" subjects_affected="56" subjects_at_risk="167"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>ABDOMINAL PAIN</sub_title>
                <counts group_id="E1" events="29" subjects_affected="14" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>CONSTIPATION</sub_title>
                <counts group_id="E1" events="175" subjects_affected="60" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>DIARRHEA</sub_title>
                <counts group_id="E1" events="127" subjects_affected="60" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>DYSPEPSIA</sub_title>
                <counts group_id="E1" events="88" subjects_affected="32" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>MUCOSITIS</sub_title>
                <counts group_id="E1" events="31" subjects_affected="17" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>NAUSEA</sub_title>
                <counts group_id="E1" events="297" subjects_affected="102" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>VOMITING</sub_title>
                <counts group_id="E1" events="54" subjects_affected="32" subjects_at_risk="167"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>CHEST PAIN</sub_title>
                <counts group_id="E1" events="16" subjects_affected="9" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>EDEMA</sub_title>
                <counts group_id="E1" events="32" subjects_affected="14" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>FATIGUE</sub_title>
                <counts group_id="E1" events="547" subjects_affected="136" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>FEVER</sub_title>
                <counts group_id="E1" events="18" subjects_affected="16" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>PAIN</sub_title>
                <counts group_id="E1" events="23" subjects_affected="13" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" events="37" subjects_affected="21" subjects_at_risk="167"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>ALLERGIC REACTION</sub_title>
                <counts group_id="E1" events="10" subjects_affected="10" subjects_at_risk="167"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>INFECTION</sub_title>
                <counts group_id="E1" events="18" subjects_affected="13" subjects_at_risk="167"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>WEIGHT LOSS</sub_title>
                <counts group_id="E1" events="22" subjects_affected="11" subjects_at_risk="167"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>ANOREXIA</sub_title>
                <counts group_id="E1" events="92" subjects_affected="41" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>DEHYDRATION</sub_title>
                <counts group_id="E1" events="12" subjects_affected="10" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>HYPERGLYCEMIA</sub_title>
                <counts group_id="E1" events="31" subjects_affected="14" subjects_at_risk="167"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>ARTHRALGIA</sub_title>
                <counts group_id="E1" events="290" subjects_affected="87" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>ASTHENIA</sub_title>
                <counts group_id="E1" events="30" subjects_affected="17" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>BACK PAIN</sub_title>
                <counts group_id="E1" events="34" subjects_affected="18" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>BONE PAIN</sub_title>
                <counts group_id="E1" events="26" subjects_affected="16" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>MYALGIA</sub_title>
                <counts group_id="E1" events="168" subjects_affected="55" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>PAIN IN EXTREMITY</sub_title>
                <counts group_id="E1" events="96" subjects_affected="40" subjects_at_risk="167"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>DIZZINESS</sub_title>
                <counts group_id="E1" events="41" subjects_affected="23" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>HEADACHE</sub_title>
                <counts group_id="E1" events="95" subjects_affected="38" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>PARESTHESIA</sub_title>
                <counts group_id="E1" events="34" subjects_affected="13" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>PERIPHERAL NEUROPATHY</sub_title>
                <counts group_id="E1" events="399" subjects_affected="117" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>TASTE ALTERATION</sub_title>
                <counts group_id="E1" events="122" subjects_affected="35" subjects_at_risk="167"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>ANXIETY</sub_title>
                <counts group_id="E1" events="79" subjects_affected="25" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>DEPRESSION</sub_title>
                <counts group_id="E1" events="40" subjects_affected="17" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>INSOMNIA</sub_title>
                <counts group_id="E1" events="145" subjects_affected="48" subjects_at_risk="167"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>BREAST PAIN</sub_title>
                <counts group_id="E1" events="34" subjects_affected="15" subjects_at_risk="167"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>ALLERGIC RHINITIS</sub_title>
                <counts group_id="E1" events="38" subjects_affected="15" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>COUGH</sub_title>
                <counts group_id="E1" events="58" subjects_affected="35" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>DYSPNEA</sub_title>
                <counts group_id="E1" events="39" subjects_affected="26" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>SORE THROAT</sub_title>
                <counts group_id="E1" events="11" subjects_affected="10" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>UPPER RESPIRATORY INFECTION</sub_title>
                <counts group_id="E1" events="16" subjects_affected="11" subjects_at_risk="167"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>ALOPECIA</sub_title>
                <counts group_id="E1" events="390" subjects_affected="100" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>NAIL CHANGES</sub_title>
                <counts group_id="E1" events="27" subjects_affected="12" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>PRURITUS</sub_title>
                <counts group_id="E1" events="22" subjects_affected="11" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>RASH</sub_title>
                <counts group_id="E1" events="53" subjects_affected="29" subjects_at_risk="167"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>HOT FLASHES</sub_title>
                <counts group_id="E1" events="79" subjects_affected="30" subjects_at_risk="167"/>
              </event>
              <event>
                <sub_title>HYPERTENSION</sub_title>
                <counts group_id="E1" events="28" subjects_affected="13" subjects_at_risk="167"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The sponsor can review/embargo results communications prior to public release for a period that is &gt;60 days but ≤180 days from the date submitted to sponsor, who may require changes to the communication in order to remove specifically identified confidential information (other than study data) and/or delay the proposed publication to enable the sponsor to seek patent protection for inventions. The PI may not publish results until 18 mos. after the trial has been completed at all sites.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>John D. Hainsworth, MD</name_or_title>
      <organization>Sarah Cannon Research Institute</organization>
      <phone>1-877-691-7274</phone>
      <email>asksarah@scresearch.net</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

